<?xml version="1.0" encoding="UTF-8"?>
<p>REGN2222 is a fully human IgG1 mAb produced in VelocImmune mice that binds specifically to the F protein of RSV. Preclinical studies in cotton rats demonstrated that REGN2222 is effective at reducing RSV viral replication in the lungs (
 <xref rid="ref59" ref-type="bibr">Gurnett-Bander et al., 2016</xref>). Although the results of two clinical trials in phase 1 in healthy adults showed that the antibody was well tolerated and it had a half-life longer than typical IgG1 mAbs with low immunogenicity (
 <xref rid="ref131" ref-type="bibr">Sivapalasingam et al., 2015</xref>), the results of a recent phase 3 trial in preterm infants revealed that this mAb did not meet its primary endpoint of preventing RSV.
</p>
